Summary

Definition and Scope:
Duchenne Muscular Dystrophy (DMD) is a severe, progressive genetic disorder characterized by muscle degeneration and weakness due to mutations in the dystrophin gene, which is essential for maintaining muscle integrity. Primarily affecting males, DMD leads to early-onset symptoms, including delayed motor development, difficulty walking, and eventual loss of ambulation, often requiring wheelchair dependence by adolescence. The condition also impacts cardiac and respiratory muscles, significantly reducing life expectancy without advanced medical intervention. Current treatments focus on symptom management, corticosteroids to slow progression, and emerging gene therapies aimed at restoring dystrophin production. The market for DMD therapies is driven by high unmet medical need, increasing genetic research, and advancements in precision medicine, with significant investment in exon-skipping drugs, gene editing technologies like CRISPR, and gene replacement therapies. Regulatory incentives, such as orphan drug designations and accelerated approvals, further stimulate innovation, though challenges remain in pricing, accessibility, and long-term efficacy of novel treatments. The competitive landscape includes pharmaceutical companies, biotech firms, and academic collaborations, with key players like Sarepta Therapeutics, Pfizer, and Solid Biosciences actively developing next-generation therapies.
This report offers a comprehensive analysis of the global Duchenne Muscular Dystrophy market, examining all key dimensions. It provides both a macro-level overview and micro-level market details, including market size, trends, competitive landscape, niche segments, growth drivers, and key challenges.

The global Duchenne Muscular Dystrophy market size was estimated at USD 2709.73 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 42.52% during the forecast period.

Report Framework and Key Highlights:
Market Dynamics: Identification of major market drivers, restraints, opportunities, and challenges.
Trend Analysis: Examination of ongoing and emerging trends impacting the market.
Competitive Landscape: Detailed profiles and market positioning of major players, including market share, operational status, product offerings, and strategic developments.
Strategic Analysis Tools: SWOT Analysis, Porter’s Five Forces Analysis, PEST Analysis, Value Chain Analysis
Market Segmentation: By type, application, region, and end-user industry.
Forecasting and Growth Projections: In-depth revenue forecasts and CAGR analysis through 2033.
This report equips readers with critical insights to navigate competitive dynamics and develop effective strategies. Whether assessing a new market entry or refining existing strategies, the report serves as a valuable tool for:
Industry players
Investors
Researchers
Consultants
Business strategists
And all stakeholders with an interest or investment in the Duchenne Muscular Dystrophy market.

Global Duchenne Muscular Dystrophy Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Companies Profiled
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals

Market Segmentation by Type
Exondys 51
Emflaza
Translarna

Market Segmentation by Application
Hospitals
Clinics
Home Care

Geographic Segmentation
North America: United States, Canada, Mexico
Europe: Germany, France, Italy, U.K., Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium, Russia.
Asia-Pacific: China, Japan, South Korea, India, Australia, Indonesia, Malaysia, Philippines, Singapore, Thailand
South America: Brazil, Argentina, Colombia.
Middle East and Africa (MEA): Saudi Arabia, United Arab Emirates, Egypt, Nigeria, South Africa, Rest of MEA

Report Framework and Chapter Summary
Chapter 1: Report Scope and Market Definition
This chapter outlines the statistical boundaries and scope of the report. It defines the segmentation standards used throughout the study, including criteria for dividing the market by region, product type, application, and other relevant dimensions. It establishes the foundational definitions and classifications that guide the rest of the analysis.
Chapter 2: Executive Summary
This chapter presents a concise summary of the market’s current status and future outlook across different segments—by geography, product type, and application. It includes key metrics such as market size, growth trends, and development potential for each segment. The chapter offers a high-level overview of the Duchenne Muscular Dystrophy Market, highlighting its evolution over the short, medium, and long term.
Chapter 3: Competitive Landscape
This chapter provides a detailed assessment of the market's competitive environment. It covers market share, production capacity, output, pricing trends, and strategic developments such as mergers, acquisitions, and expansion plans of leading players. This analysis offers a comprehensive view of the positioning and performance of top competitors.
Chapter 4: Industry Chain and Value Chain Analysis
This chapter explores the full industry chain, from upstream raw material suppliers to downstream application sectors. It includes a value chain analysis that highlights the interconnections and dependencies across various parts of the ecosystem.
Chapter 5: Market Dynamics and Policy Environment
This chapter explores the latest developments in the market, identifying key growth drivers, restraints, challenges, and risks faced by industry participants. It also includes an analysis of the policy and regulatory landscape affecting the market, providing insight into how external factors may shape future performance.
Chapter 6: Market Segmentation by Product Type
This chapter examines the market based on product type, analyzing the size, growth trends, and potential of each segment. It helps stakeholders identify underexplored or high-potential product categories—often referred to as “blue ocean” opportunities.
Chapter 7: Market Segmentation by Application
This chapter analyzes the market based on application fields, providing insights into the scale and future development of each application segment. It supports readers in identifying high-growth areas across downstream markets.
Chapters 8: Regional Market Analysis by Consumption
These chapters offer in-depth, quantitative evaluations of market size and growth potential across major regions and countries. Each chapter assesses regional consumption patterns, market dynamics, development prospects, and available capacity. The analysis helps readers understand geographical differences and opportunities in global markets.
Chapter 9: Regional Market Analysis by Production
These chapters shares the main producing countries of Duchenne Muscular Dystrophy, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10: Company Profiles
This chapter presents comprehensive profiles of leading companies operating in the market. For each company, it details sales revenue, volume, pricing, gross profit margin, market share, product offerings, and recent strategic developments. This section offers valuable insight into corporate performance and strategy.
Chapter 12: Key Findings and Conclusions
The final chapter summarizes the main takeaways from the report, presenting the core conclusions, strategic recommendations, and implications for stakeholders. It encapsulates the insights drawn from all previous chapters.

ページTOPに戻る

Table of Contents

Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Duchenne Muscular Dystrophy Drugs
1.2 Key Market Segments
1.2.1 Duchenne Muscular Dystrophy Drugs Segment by Type
1.2.2 Duchenne Muscular Dystrophy Drugs Segment by Application
1.3 Methodology & Sources of Information

2

3 Global Duchenne Muscular Dystrophy Drugs Market Overview
3.1 Global Duchenne Muscular Dystrophy Drugs Market Overview
3.1.1 Global Duchenne Muscular Dystrophy Drugs Market Size and Forecasts (2020-2035)
3.1.2 Global Duchenne Muscular Dystrophy Drugs Market: Capacity and Utilization Outlook (2020–2035)
3.2 Market Segment Executive Summary
3.3 Global Market Size by Region

4 Duchenne Muscular Dystrophy Drugs Market Competitive Landscape
4.1 Company Assessment Quadrant
4.2 Global Duchenne Muscular Dystrophy Drugs Product Life Cycle
4.3 Global Duchenne Muscular Dystrophy Drugs Sales by Manufacturers (2020-2025)
4.4 Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Manufacturers (2020-2025)
4.5 Duchenne Muscular Dystrophy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.6 Global Duchenne Muscular Dystrophy Drugs Average Price by Manufacturers (2020-2025)
4.7 Production Capacity and Capacity Utilization Rate of Major Duchenne Muscular Dystrophy Drugs Manufacturers
4.8 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
4.9 Duchenne Muscular Dystrophy Drugs Market Competitive Situation and Trends
4.9.1 Duchenne Muscular Dystrophy Drugs Market Concentration Rate
4.9.2 Global 5 and 10 Largest Duchenne Muscular Dystrophy Drugs Players Market Share by Revenue
4.9.3 Mergers & Acquisitions, Expansion

5 Duchenne Muscular Dystrophy Drugs Industry Chain Analysis
5.1 Duchenne Muscular Dystrophy Drugs Industry Chain Analysis
5.2 Market Overview of Key Raw Materials
5.3 Midstream Market Analysis
5.4 Downstream Customer Analysis

6 The Development and Dynamics of Duchenne Muscular Dystrophy Drugs Market
6.1 Key Development Trends
6.2 Driving Factors
6.3 Market Challenges
6.4 Industry News
6.4.1 New Product Developments
6.4.2 Mergers & Acquisitions
6.4.3 Expansions
6.4.4 Collaboration/Supply Contracts
6.5 PEST Analysis
6.5.1 Political Environment Analysis
6.5.2 Economic Environment Analysis
6.5.3 Social Environment Analysis
6.5.4 Technological Environment Analysis
6.6 Global Duchenne Muscular Dystrophy Drugs Market Porter's Five Forces Analysis
6.6.1 Global Trade Frictions
6.6.2 U.S. Tariff Policy
6.6.3 Global Trade Frictions and Their Impacts on Duchenne Muscular Dystrophy Drugs Market

7 Duchenne Muscular Dystrophy Drugs Market Segmentation by Type
7.1 Evaluation Matrix of Segment Market Development Potential (Type)
7.2 Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2020-2025)
7.3 Global Duchenne Muscular Dystrophy Drugs Market Size by Type (2020-2025)
7.4 Global Duchenne Muscular Dystrophy Drugs Price by Type (2020-2025)

8 Duchenne Muscular Dystrophy Drugs Market Segmentation by Application
8.1 Evaluation Matrix of Segment Market Development Potential (Application)
8.2 Global Duchenne Muscular Dystrophy Drugs Market Sales by Application (2020-2025)
8.3 Global Duchenne Muscular Dystrophy Drugs Market Size (M USD) by Application (2020-2025)
8.4 Global Duchenne Muscular Dystrophy Drugs Sales Growth Rate by Application (2020-2025)

9 Duchenne Muscular Dystrophy Drugs Market Segmentation by Region
9.1 Global Duchenne Muscular Dystrophy Drugs Sales by Region
9.1.1 Global Duchenne Muscular Dystrophy Drugs Sales by Region
9.1.2 Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Region
9.2 Global Duchenne Muscular Dystrophy Drugs Market Size by Region
9.2.1 Global Duchenne Muscular Dystrophy Drugs Market Size by Region
9.2.2 Global Duchenne Muscular Dystrophy Drugs Market Size by Region
9.3 North America
9.3.1 North America Duchenne Muscular Dystrophy Drugs Sales by Country
9.3.2 North America Duchenne Muscular Dystrophy Drugs Market Size by Country
9.3.3 U.S. Market Overview
9.3.4 Canada Market Overview
9.3.5 Mexico Market Overview
9.4 Europe
9.4.1 Europe Duchenne Muscular Dystrophy Drugs Sales by Country
9.4.2 Europe Duchenne Muscular Dystrophy Drugs Market Size by Country
9.4.3 Germany Market Overview
9.4.4 France Market Overview
9.4.5 U.K. Market Overview
9.4.6 Italy Market Overview
9.4.7 Spain Market Overview
9.5 Asia Pacific
9.5.1 Asia Pacific Duchenne Muscular Dystrophy Drugs Sales by Region
9.5.2 Asia Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region
9.5.3 China Market Overview
9.5.4 Japan Market Overview
9.5.5 South Korea Market Overview
9.5.6 India Market Overview
9.5.7 Southeast Asia Market Overview
9.6 South America
9.6.1 South America Duchenne Muscular Dystrophy Drugs Sales by Country
9.6.2 South America Duchenne Muscular Dystrophy Drugs Market Size by Country
9.6.3 Brazil Market Overview
9.6.4 Argentina Market Overview
9.6.5 Columbia Market Overview
9.7 Middle East and Africa
9.7.1 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales by Region
9.7.2 Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Size by Region
9.7.3 Saudi Arabia Market Overview
9.7.4 UAE Market Overview
9.7.5 Egypt Market Overview
9.7.6 Nigeria Market Overview
9.7.7 South Africa Market Overview

10 Duchenne Muscular Dystrophy Drugs Market Production by Region
10.1 Global Production of Duchenne Muscular Dystrophy Drugs by Region(2020-2025)
10.2 Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Region (2020-2025)
10.3 Global Duchenne Muscular Dystrophy Drugs Production, Revenue, Price and Gross Margin (2020-2025)
10.4 North America Duchenne Muscular Dystrophy Drugs Production
10.4.1 North America Duchenne Muscular Dystrophy Drugs Production Growth Rate (2020-2025)
10.4.2 North America Duchenne Muscular Dystrophy Drugs Production, Revenue, Price and Gross Margin (2020-2025)
10.5 Europe Duchenne Muscular Dystrophy Drugs Production
10.5.1 Europe Duchenne Muscular Dystrophy Drugs Production Growth Rate (2020-2025)
10.5.2 Europe Duchenne Muscular Dystrophy Drugs Production, Revenue, Price and Gross Margin (2020-2025)
10.6 Japan Duchenne Muscular Dystrophy Drugs Production (2020-2025)
10.6.1 Japan Duchenne Muscular Dystrophy Drugs Production Growth Rate (2020-2025)
10.6.2 Japan Duchenne Muscular Dystrophy Drugs Production, Revenue, Price and Gross Margin (2020-2025)
10.7 China Duchenne Muscular Dystrophy Drugs Production (2020-2025)
10.7.1 China Duchenne Muscular Dystrophy Drugs Production Growth Rate (2020-2025)
10.7.2 China Duchenne Muscular Dystrophy Drugs Production, Revenue, Price and Gross Margin (2020-2025)

11 Key Companies Profile
11.1 Akashi Therapeutics Inc
11.1.1 Akashi Therapeutics Inc Basic Information
11.1.2 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Overview
11.1.3 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Market Performance
11.1.4 Akashi Therapeutics Inc Business Overview
11.1.5 Akashi Therapeutics Inc SWOT Analysis
11.1.6 Akashi Therapeutics Inc Recent Developments
11.2 Antisense Therapeutics Ltd
11.2.1 Antisense Therapeutics Ltd Basic Information
11.2.2 Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Product Overview
11.2.3 Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Product Market Performance
11.2.4 Antisense Therapeutics Ltd Business Overview
11.2.5 Antisense Therapeutics Ltd SWOT Analysis
11.2.6 Antisense Therapeutics Ltd Recent Developments
11.3 Beech Tree Labs Inc
11.3.1 Beech Tree Labs Inc Basic Information
11.3.2 Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Product Overview
11.3.3 Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Product Market Performance
11.3.4 Beech Tree Labs Inc Business Overview
11.3.5 Beech Tree Labs Inc SWOT Analysis
11.3.6 Beech Tree Labs Inc Recent Developments
11.4 Biogen Inc
11.4.1 Biogen Inc Basic Information
11.4.2 Biogen Inc Duchenne Muscular Dystrophy Drugs Product Overview
11.4.3 Biogen Inc Duchenne Muscular Dystrophy Drugs Product Market Performance
11.4.4 Biogen Inc Business Overview
11.4.5 Biogen Inc Recent Developments
11.5 Bioleaders Corp
11.5.1 Bioleaders Corp Basic Information
11.5.2 Bioleaders Corp Duchenne Muscular Dystrophy Drugs Product Overview
11.5.3 Bioleaders Corp Duchenne Muscular Dystrophy Drugs Product Market Performance
11.5.4 Bioleaders Corp Business Overview
11.5.5 Bioleaders Corp Recent Developments
11.6 BioMarin Pharmaceutical Inc
11.6.1 BioMarin Pharmaceutical Inc Basic Information
11.6.2 BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Product Overview
11.6.3 BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Product Market Performance
11.6.4 BioMarin Pharmaceutical Inc Business Overview
11.6.5 BioMarin Pharmaceutical Inc Recent Developments
11.7 Biophytis SAS
11.7.1 Biophytis SAS Basic Information
11.7.2 Biophytis SAS Duchenne Muscular Dystrophy Drugs Product Overview
11.7.3 Biophytis SAS Duchenne Muscular Dystrophy Drugs Product Market Performance
11.7.4 Biophytis SAS Business Overview
11.7.5 Biophytis SAS Recent Developments
11.8 Capricor Therapeutics Inc
11.8.1 Capricor Therapeutics Inc Basic Information
11.8.2 Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Overview
11.8.3 Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Market Performance
11.8.4 Capricor Therapeutics Inc Business Overview
11.8.5 Capricor Therapeutics Inc Recent Developments
11.9 Catabasis Pharmaceuticals Inc
11.9.1 Catabasis Pharmaceuticals Inc Basic Information
11.9.2 Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product Overview
11.9.3 Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product Market Performance
11.9.4 Catabasis Pharmaceuticals Inc Business Overview
11.9.5 Catabasis Pharmaceuticals Inc Recent Developments
11.10 CRISPR Therapeutics
11.10.1 CRISPR Therapeutics Basic Information
11.10.2 CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Product Overview
11.10.3 CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Product Market Performance
11.10.4 CRISPR Therapeutics Business Overview
11.10.5 CRISPR Therapeutics Recent Developments
11.11 Cumberland Pharmaceuticals Inc
11.11.1 Cumberland Pharmaceuticals Inc Basic Information
11.11.2 Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product Overview
11.11.3 Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product Market Performance
11.11.4 Cumberland Pharmaceuticals Inc Business Overview
11.11.5 Cumberland Pharmaceuticals Inc Recent Developments
11.12 Daiichi Sankyo Co Ltd
11.12.1 Daiichi Sankyo Co Ltd Basic Information
11.12.2 Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Product Overview
11.12.3 Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Product Market Performance
11.12.4 Daiichi Sankyo Co Ltd Business Overview
11.12.5 Daiichi Sankyo Co Ltd Recent Developments
11.13 Debiopharm International SA
11.13.1 Debiopharm International SA Basic Information
11.13.2 Debiopharm International SA Duchenne Muscular Dystrophy Drugs Product Overview
11.13.3 Debiopharm International SA Duchenne Muscular Dystrophy Drugs Product Market Performance
11.13.4 Debiopharm International SA Business Overview
11.13.5 Debiopharm International SA Recent Developments
11.14 Editas Medicine Inc
11.14.1 Editas Medicine Inc Basic Information
11.14.2 Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Product Overview
11.14.3 Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Product Market Performance
11.14.4 Editas Medicine Inc Business Overview
11.14.5 Editas Medicine Inc Recent Developments
11.15 Eloxx Pharmaceuticals Inc
11.15.1 Eloxx Pharmaceuticals Inc Basic Information
11.15.2 Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product Overview
11.15.3 Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product Market Performance
11.15.4 Eloxx Pharmaceuticals Inc Business Overview
11.15.5 Eloxx Pharmaceuticals Inc Recent Developments
11.16 F. Hoffmann-La Roche Ltd
11.16.1 F. Hoffmann-La Roche Ltd Basic Information
11.16.2 F. Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Product Overview
11.16.3 F. Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Product Market Performance
11.16.4 F. Hoffmann-La Roche Ltd Business Overview
11.16.5 F. Hoffmann-La Roche Ltd Recent Developments
11.17 FibroGen Inc
11.17.1 FibroGen Inc Basic Information
11.17.2 FibroGen Inc Duchenne Muscular Dystrophy Drugs Product Overview
11.17.3 FibroGen Inc Duchenne Muscular Dystrophy Drugs Product Market Performance
11.17.4 FibroGen Inc Business Overview
11.17.5 FibroGen Inc Recent Developments
11.18 Fulcrum Therapeutics Inc
11.18.1 Fulcrum Therapeutics Inc Basic Information
11.18.2 Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Overview
11.18.3 Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Market Performance
11.18.4 Fulcrum Therapeutics Inc Business Overview
11.18.5 Fulcrum Therapeutics Inc Recent Developments
11.19 Galapagos NV
11.19.1 Galapagos NV Basic Information
11.19.2 Galapagos NV Duchenne Muscular Dystrophy Drugs Product Overview
11.19.3 Galapagos NV Duchenne Muscular Dystrophy Drugs Product Market Performance
11.19.4 Galapagos NV Business Overview
11.19.5 Galapagos NV Recent Developments
11.20 Genethon SA
11.20.1 Genethon SA Basic Information
11.20.2 Genethon SA Duchenne Muscular Dystrophy Drugs Product Overview
11.20.3 Genethon SA Duchenne Muscular Dystrophy Drugs Product Market Performance
11.20.4 Genethon SA Business Overview
11.20.5 Genethon SA Recent Developments
11.21 GTx Inc
11.21.1 GTx Inc Basic Information
11.21.2 GTx Inc Duchenne Muscular Dystrophy Drugs Product Overview
11.21.3 GTx Inc Duchenne Muscular Dystrophy Drugs Product Market Performance
11.21.4 GTx Inc Business Overview
11.21.5 GTx Inc Recent Developments
11.22 Santhera Pharmaceuticals Holding AG
11.22.1 Santhera Pharmaceuticals Holding AG Basic Information
11.22.2 Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Product Overview
11.22.3 Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Product Market Performance
11.22.4 Santhera Pharmaceuticals Holding AG Business Overview
11.22.5 Santhera Pharmaceuticals Holding AG Recent Developments
11.23 Sarepta Therapeutics Inc
11.23.1 Sarepta Therapeutics Inc Basic Information
11.23.2 Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Overview
11.23.3 Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Market Performance
11.23.4 Sarepta Therapeutics Inc Business Overview
11.23.5 Sarepta Therapeutics Inc Recent Developments
11.24 SOM Biotech SL
11.24.1 SOM Biotech SL Basic Information
11.24.2 SOM Biotech SL Duchenne Muscular Dystrophy Drugs Product Overview
11.24.3 SOM Biotech SL Duchenne Muscular Dystrophy Drugs Product Market Performance
11.24.4 SOM Biotech SL Business Overview
11.24.5 SOM Biotech SL Recent Developments
11.25 Strykagen Corp
11.25.1 Strykagen Corp Basic Information
11.25.2 Strykagen Corp Duchenne Muscular Dystrophy Drugs Product Overview
11.25.3 Strykagen Corp Duchenne Muscular Dystrophy Drugs Product Market Performance
11.25.4 Strykagen Corp Business Overview
11.25.5 Strykagen Corp Recent Developments
11.26 Summit Therapeutics Plc
11.26.1 Summit Therapeutics Plc Basic Information
11.26.2 Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Product Overview
11.26.3 Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Product Market Performance
11.26.4 Summit Therapeutics Plc Business Overview
11.26.5 Summit Therapeutics Plc Recent Developments
11.27 Taiho Pharmaceutical Co Ltd
11.27.1 Taiho Pharmaceutical Co Ltd Basic Information
11.27.2 Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Product Overview
11.27.3 Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Product Market Performance
11.27.4 Taiho Pharmaceutical Co Ltd Business Overview
11.27.5 Taiho Pharmaceutical Co Ltd Recent Developments
11.28 Teijin Pharma Ltd
11.28.1 Teijin Pharma Ltd Basic Information
11.28.2 Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Product Overview
11.28.3 Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Product Market Performance
11.28.4 Teijin Pharma Ltd Business Overview
11.28.5 Teijin Pharma Ltd Recent Developments
11.29 WAVE Life Sciences Ltd
11.29.1 WAVE Life Sciences Ltd Basic Information
11.29.2 WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Product Overview
11.29.3 WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Product Market Performance
11.29.4 WAVE Life Sciences Ltd Business Overview
11.29.5 WAVE Life Sciences Ltd Recent Developments

12 Duchenne Muscular Dystrophy Drugs Market Forecast by Region
12.1 Global Duchenne Muscular Dystrophy Drugs Market Size Forecast
12.2 Global Duchenne Muscular Dystrophy Drugs Market Forecast by Region
12.2.1 North America Market Size Forecast by Country
12.2.2 Europe Duchenne Muscular Dystrophy Drugs Market Size Forecast by Country
12.2.3 Asia Pacific Duchenne Muscular Dystrophy Drugs Market Size Forecast by Region
12.2.4 South America Duchenne Muscular Dystrophy Drugs Market Size Forecast by Country
12.2.5 Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Size Forecast by Country

13 Forecast Market by Type and by Application (2026-2035)
13.1 Global Duchenne Muscular Dystrophy Drugs Market Forecast by Type (2026-2035)
13.1.1 Global Forecasted Sales of Duchenne Muscular Dystrophy Drugs by Type (2026-2035)
13.1.2 Global Duchenne Muscular Dystrophy Drugs Market Size Forecast by Type (2026-2035)
13.1.3 Global Forecasted Price of Duchenne Muscular Dystrophy Drugs by Type (2026-2035)
13.2 Global Duchenne Muscular Dystrophy Drugs Market Forecast by Application (2026-2035)
13.2.1 Global Duchenne Muscular Dystrophy Drugs Sales (K MT) Forecast by Application
13.2.2 Global Duchenne Muscular Dystrophy Drugs Market Size (M USD) Forecast by Application (2026-2035)

14 Conclusion and Key Findings

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Duchenne Muscular Dystrophy Drugs Market Size by Type (M USD)
Table 4. Global Duchenne Muscular Dystrophy Drugs Market Size by Application
Table 5. Duchenne Muscular Dystrophy Drugs Market Size Comparison by Region (M USD)
Table 6. Duchenne Muscular Dystrophy Drugs Market Size by Country (M USD)
Table 7. Global Duchenne Muscular Dystrophy Drugs Sales (K MT) by Manufacturers (2020-2025)
Table 8. Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Manufacturers (2020-2025)
Table 9. Global Duchenne Muscular Dystrophy Drugs Revenue (M USD) by Manufacturers (2020-2025)
Table 10. Global Duchenne Muscular Dystrophy Drugs Revenue Share by Manufacturers (2020-2025)
Table 11. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy Drugs as of 2025)
Table 12. Global Market Duchenne Muscular Dystrophy Drugs Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 13. Production Capacity and Capacity Utilization Rate of Major Duchenne Muscular Dystrophy Drugs Manufacturers in 2024
Table 14. Manufacturers’ Manufacturing Sites, Areas Served
Table 15. Manufacturers’ Product Type
Table 16. Global Duchenne Muscular Dystrophy Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Mergers & Acquisitions, Expansion Plans
Table 18. Market Overview of Key Raw Materials
Table 19. Midstream Market Lists
Table 20. Downstream Customer Analysis
Table 21. Key Development Trends
Table 22. Driving Factors
Table 23. Duchenne Muscular Dystrophy Drugs Market Challenges
Table 24. World Bank's Forecast Real GDP Growth Rate for 2024-2028
Table 25. Goldman Sachs' Forecast Real GDP Growth Rate for 2025-2026
Table 26. IMF's Forecast Real GDP Growth Rate For 2024-2026
Table 27. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 28. Global Duchenne Muscular Dystrophy Drugs Sales by Type (K MT)
Table 29. Global Duchenne Muscular Dystrophy Drugs Market Size by Type (M USD)
Table 30. Global Duchenne Muscular Dystrophy Drugs Sales (K MT) by Type (2020-2025)
Table 31. Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2020-2025)
Table 32. Global Duchenne Muscular Dystrophy Drugs Market Size (M USD) by Type (2020-2025)
Table 33. Global Duchenne Muscular Dystrophy Drugs Market Share by Type (2020-2025)
Table 34. Global Duchenne Muscular Dystrophy Drugs Price (USD/KG) by Type (2020-2025)
Table 35. Global Duchenne Muscular Dystrophy Drugs Sales (K MT) by Application
Table 36. Global Duchenne Muscular Dystrophy Drugs Market Size by Application
Table 37. Global Duchenne Muscular Dystrophy Drugs Sales by Application (2020-2025) & (K MT)
Table 38. Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2020-2025)
Table 39. Global Duchenne Muscular Dystrophy Drugs Market Size by Application (2020-2025) & (M USD)
Table 40. Global Duchenne Muscular Dystrophy Drugs Market Share by Application (2020-2025)
Table 41. Global Duchenne Muscular Dystrophy Drugs Sales Growth Rate by Application (2020-2025)
Table 42. Global Duchenne Muscular Dystrophy Drugs Sales by Region (2020-2025) & (K MT)
Table 43. Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Region (2020-2025)
Table 44. Global Duchenne Muscular Dystrophy Drugs Market Size by Region (2020-2025) & (M USD)
Table 45. Global Duchenne Muscular Dystrophy Drugs Market Size by Region (2020-2025)
Table 46. North America Duchenne Muscular Dystrophy Drugs Sales by Country (2020-2025) & (K MT)
Table 47. North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2020-2025) & (M USD)
Table 48. Europe Duchenne Muscular Dystrophy Drugs Sales by Country (2020-2025) & (K MT)
Table 49. Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2020-2025) & (M USD)
Table 50. Asia Pacific Duchenne Muscular Dystrophy Drugs Sales by Region (2020-2025) & (K MT)
Table 51. Asia Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2020-2025) & (M USD)
Table 52. South America Duchenne Muscular Dystrophy Drugs Sales by Country (2020-2025) & (K MT)
Table 53. South America Duchenne Muscular Dystrophy Drugs Market Size by Country (2020-2025) & (M USD)
Table 54. Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales by Region (2020-2025) & (K MT)
Table 55. Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Size by Region (2020-2025) & (M USD)
Table 56. Global Duchenne Muscular Dystrophy Drugs Production (K MT) by Region(2020-2025)
Table 57. Global Duchenne Muscular Dystrophy Drugs Revenue (US$ Million) by Region (2020-2025)
Table 58. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Region (2020-2025)
Table 59. Global Duchenne Muscular Dystrophy Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. North America Duchenne Muscular Dystrophy Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. Europe Duchenne Muscular Dystrophy Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Japan Duchenne Muscular Dystrophy Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 63. China Duchenne Muscular Dystrophy Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 64. Akashi Therapeutics Inc Basic Information
Table 65. Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Overview
Table 66. Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 67. Akashi Therapeutics Inc Business Overview
Table 68. Akashi Therapeutics Inc SWOT Analysis
Table 69. Akashi Therapeutics Inc Recent Developments
Table 70. Antisense Therapeutics Ltd Basic Information
Table 71. Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Product Overview
Table 72. Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 73. Antisense Therapeutics Ltd Business Overview
Table 74. Antisense Therapeutics Ltd SWOT Analysis
Table 75. Antisense Therapeutics Ltd Recent Developments
Table 76. Beech Tree Labs Inc Basic Information
Table 77. Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Product Overview
Table 78. Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 79. Beech Tree Labs Inc Business Overview
Table 80. Beech Tree Labs Inc SWOT Analysis
Table 81. Beech Tree Labs Inc Recent Developments
Table 82. Biogen Inc Basic Information
Table 83. Biogen Inc Duchenne Muscular Dystrophy Drugs Product Overview
Table 84. Biogen Inc Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 85. Biogen Inc Business Overview
Table 86. Biogen Inc Recent Developments
Table 87. Bioleaders Corp Basic Information
Table 88. Bioleaders Corp Duchenne Muscular Dystrophy Drugs Product Overview
Table 89. Bioleaders Corp Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 90. Bioleaders Corp Business Overview
Table 91. Bioleaders Corp Recent Developments
Table 92. BioMarin Pharmaceutical Inc Basic Information
Table 93. BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Product Overview
Table 94. BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 95. BioMarin Pharmaceutical Inc Business Overview
Table 96. BioMarin Pharmaceutical Inc Recent Developments
Table 97. Biophytis SAS Basic Information
Table 98. Biophytis SAS Duchenne Muscular Dystrophy Drugs Product Overview
Table 99. Biophytis SAS Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 100. Biophytis SAS Business Overview
Table 101. Biophytis SAS Recent Developments
Table 102. Capricor Therapeutics Inc Basic Information
Table 103. Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Overview
Table 104. Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 105. Capricor Therapeutics Inc Business Overview
Table 106. Capricor Therapeutics Inc Recent Developments
Table 107. Catabasis Pharmaceuticals Inc Basic Information
Table 108. Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product Overview
Table 109. Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 110. Catabasis Pharmaceuticals Inc Business Overview
Table 111. Catabasis Pharmaceuticals Inc Recent Developments
Table 112. CRISPR Therapeutics Basic Information
Table 113. CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Product Overview
Table 114. CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 115. CRISPR Therapeutics Business Overview
Table 116. CRISPR Therapeutics Recent Developments
Table 117. Cumberland Pharmaceuticals Inc Basic Information
Table 118. Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product Overview
Table 119. Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 120. Cumberland Pharmaceuticals Inc Business Overview
Table 121. Cumberland Pharmaceuticals Inc Recent Developments
Table 122. Daiichi Sankyo Co Ltd Basic Information
Table 123. Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Product Overview
Table 124. Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 125. Daiichi Sankyo Co Ltd Business Overview
Table 126. Daiichi Sankyo Co Ltd Recent Developments
Table 127. Debiopharm International SA Basic Information
Table 128. Debiopharm International SA Duchenne Muscular Dystrophy Drugs Product Overview
Table 129. Debiopharm International SA Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 130. Debiopharm International SA Business Overview
Table 131. Debiopharm International SA Recent Developments
Table 132. Editas Medicine Inc Basic Information
Table 133. Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Product Overview
Table 134. Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 135. Editas Medicine Inc Business Overview
Table 136. Editas Medicine Inc Recent Developments
Table 137. Eloxx Pharmaceuticals Inc Basic Information
Table 138. Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product Overview
Table 139. Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 140. Eloxx Pharmaceuticals Inc Business Overview
Table 141. Eloxx Pharmaceuticals Inc Recent Developments
Table 142. F. Hoffmann-La Roche Ltd Basic Information
Table 143. F. Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Product Overview
Table 144. F. Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 145. F. Hoffmann-La Roche Ltd Business Overview
Table 146. F. Hoffmann-La Roche Ltd Recent Developments
Table 147. FibroGen Inc Basic Information
Table 148. FibroGen Inc Duchenne Muscular Dystrophy Drugs Product Overview
Table 149. FibroGen Inc Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 150. FibroGen Inc Business Overview
Table 151. FibroGen Inc Recent Developments
Table 152. Fulcrum Therapeutics Inc Basic Information
Table 153. Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Overview
Table 154. Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 155. Fulcrum Therapeutics Inc Business Overview
Table 156. Fulcrum Therapeutics Inc Recent Developments
Table 157. Galapagos NV Basic Information
Table 158. Galapagos NV Duchenne Muscular Dystrophy Drugs Product Overview
Table 159. Galapagos NV Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 160. Galapagos NV Business Overview
Table 161. Galapagos NV Recent Developments
Table 162. Genethon SA Basic Information
Table 163. Genethon SA Duchenne Muscular Dystrophy Drugs Product Overview
Table 164. Genethon SA Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 165. Genethon SA Business Overview
Table 166. Genethon SA Recent Developments
Table 167. GTx Inc Basic Information
Table 168. GTx Inc Duchenne Muscular Dystrophy Drugs Product Overview
Table 169. GTx Inc Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 170. GTx Inc Business Overview
Table 171. GTx Inc Recent Developments
Table 172. Santhera Pharmaceuticals Holding AG Basic Information
Table 173. Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Product Overview
Table 174. Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 175. Santhera Pharmaceuticals Holding AG Business Overview
Table 176. Santhera Pharmaceuticals Holding AG Recent Developments
Table 177. Sarepta Therapeutics Inc Basic Information
Table 178. Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Overview
Table 179. Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 180. Sarepta Therapeutics Inc Business Overview
Table 181. Sarepta Therapeutics Inc Recent Developments
Table 182. SOM Biotech SL Basic Information
Table 183. SOM Biotech SL Duchenne Muscular Dystrophy Drugs Product Overview
Table 184. SOM Biotech SL Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 185. SOM Biotech SL Business Overview
Table 186. SOM Biotech SL Recent Developments
Table 187. Strykagen Corp Basic Information
Table 188. Strykagen Corp Duchenne Muscular Dystrophy Drugs Product Overview
Table 189. Strykagen Corp Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 190. Strykagen Corp Business Overview
Table 191. Strykagen Corp Recent Developments
Table 192. Summit Therapeutics Plc Basic Information
Table 193. Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Product Overview
Table 194. Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 195. Summit Therapeutics Plc Business Overview
Table 196. Summit Therapeutics Plc Recent Developments
Table 197. Taiho Pharmaceutical Co Ltd Basic Information
Table 198. Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Product Overview
Table 199. Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 200. Taiho Pharmaceutical Co Ltd Business Overview
Table 201. Taiho Pharmaceutical Co Ltd Recent Developments
Table 202. Teijin Pharma Ltd Basic Information
Table 203. Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Product Overview
Table 204. Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 205. Teijin Pharma Ltd Business Overview
Table 206. Teijin Pharma Ltd Recent Developments
Table 207. WAVE Life Sciences Ltd Basic Information
Table 208. WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Product Overview
Table 209. WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 210. WAVE Life Sciences Ltd Business Overview
Table 211. WAVE Life Sciences Ltd Recent Developments
Table 212. Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Region (2026-2035) & (K MT)
Table 213. Global Duchenne Muscular Dystrophy Drugs Market Size Forecast by Region (2026-2035) & (M USD)
Table 214. North America Duchenne Muscular Dystrophy Drugs Sales Forecast by Country (2026-2035) & (K MT)
Table 215. North America Duchenne Muscular Dystrophy Drugs Market Size Forecast by Country (2026-2035) & (M USD)
Table 216. Europe Duchenne Muscular Dystrophy Drugs Sales Forecast by Country (2026-2035) & (K MT)
Table 217. Europe Duchenne Muscular Dystrophy Drugs Market Size Forecast by Country (2026-2035) & (M USD)
Table 218. Asia Pacific Duchenne Muscular Dystrophy Drugs Sales Forecast by Region (2026-2035) & (K MT)
Table 219. Asia Pacific Duchenne Muscular Dystrophy Drugs Market Size Forecast by Region (2026-2035) & (M USD)
Table 220. South America Duchenne Muscular Dystrophy Drugs Sales Forecast by Country (2026-2035) & (K MT)
Table 221. South America Duchenne Muscular Dystrophy Drugs Market Size Forecast by Country (2026-2035) & (M USD)
Table 222. Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales Forecast by Country (2026-2035) & (K MT)
Table 223. Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Size Forecast by Country (2026-2035) & (M USD)
Table 224. Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Type (2026-2035) & (K MT)
Table 225. Global Duchenne Muscular Dystrophy Drugs Market Size Forecast by Type (2026-2035) & (M USD)
Table 226. Global Duchenne Muscular Dystrophy Drugs Price Forecast by Type (2026-2035) & (USD/KG)
Table 227. Global Duchenne Muscular Dystrophy Drugs Sales (K MT) Forecast by Application (2026-2035)
Table 228. Global Duchenne Muscular Dystrophy Drugs Market Size Forecast by Application (2026-2035) & (M USD)
List of Figures
Figure 1. Product Picture of Duchenne Muscular Dystrophy Drugs
Figure 2. Global Duchenne Muscular Dystrophy Drugs Market Size (M USD) (2020-2035)
Figure 3. Global Duchenne Muscular Dystrophy Drugs Sales (K MT) & (2020-2035)
Figure 4. Global Duchenne Muscular Dystrophy Drugs Market: Capacity and Utilization Outlook (2020-2035)
Figure 5. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 6. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 7. Evaluation Matrix of Regional Market Development Potential
Figure 8. Company Assessment Quadrant
Figure 9. Global Duchenne Muscular Dystrophy Drugs Product Life Cycle
Figure 10. Duchenne Muscular Dystrophy Drugs Sales Share by Manufacturers in 2025
Figure 11. Global Duchenne Muscular Dystrophy Drugs Revenue Share by Manufacturers in 2025
Figure 12. Duchenne Muscular Dystrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 13. Global Market Duchenne Muscular Dystrophy Drugs Average Price (USD/KG) of Key Manufacturers in 2025
Figure 14. The Global 5 and 10 Largest Players: Market Share by Duchenne Muscular Dystrophy Drugs Revenue in 2025
Figure 15. Industry Chain Map of Duchenne Muscular Dystrophy Drugs
Figure 16. Duchenne Muscular Dystrophy Drugs Market Share of Key Raw Materials (2025)
Figure 17. Key Driving Factors - Impact Assessment
Figure 18. Market Challenges - Severity vs. Frequency Matrix
Figure 19. Key Industry News Timeline
Figure 20. Global Duchenne Muscular Dystrophy Drugs Market PEST Analysis
Figure 21. Global Duchenne Muscular Dystrophy Drugs Market Porter's Five Forces Analysis
Figure 22. Global Merchandise Trade as a Percentage Of GDP
Figure 23. US - lmports of Goods by Country
Figure 24. China Exports by Country
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Duchenne Muscular Dystrophy Drugs Market Share by Type
Figure 27. Sales Market Share of Duchenne Muscular Dystrophy Drugs by Type (2020-2025)
Figure 28. Sales Market Share of Duchenne Muscular Dystrophy Drugs by Type in 2025
Figure 29. Market Share of Duchenne Muscular Dystrophy Drugs by Type (2020-2025)
Figure 30. Market Share of Duchenne Muscular Dystrophy Drugs by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Duchenne Muscular Dystrophy Drugs Market Share by Application
Figure 33. Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2020-2025)
Figure 34. Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Application in 2025
Figure 35. Global Duchenne Muscular Dystrophy Drugs Market Share by Application (2020-2025)
Figure 36. Global Duchenne Muscular Dystrophy Drugs Market Share by Application in 2025
Figure 37. Global Duchenne Muscular Dystrophy Drugs Sales Growth Rate by Application (2020-2025)
Figure 38. Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Region (2020-2025)
Figure 39. Global Duchenne Muscular Dystrophy Drugs Market Size by Region (2020-2025)
Figure 40. North America Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Duchenne Muscular Dystrophy Drugs Sales Market Share by Country in 2024
Figure 42. North America Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 43. North America Duchenne Muscular Dystrophy Drugs Market Size by Country in 2024
Figure 44. U.S. Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 45. U.S. Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 46. Canada Duchenne Muscular Dystrophy Drugs Sales (K MT) and Growth Rate (2020-2025)
Figure 47. Canada Duchenne Muscular Dystrophy Drugs Market Size (M USD) and Growth Rate (2020-2025)
Figure 48. Mexico Duchenne Muscular Dystrophy Drugs Sales (K MT) and Growth Rate (2020-2025)
Figure 49. Mexico Duchenne Muscular Dystrophy Drugs Market Size (M USD) and Growth Rate (2020-2025)
Figure 50. Europe Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 51. Europe Duchenne Muscular Dystrophy Drugs Sales Market Share by Country in 2024
Figure 52. Europe Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 53. Europe Duchenne Muscular Dystrophy Drugs Market Size by Country in 2024
Figure 54. Germany Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 55. Germany Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 56. France Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 57. France Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 58. U.K. Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 59. U.K. Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 60. Italy Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 61. Italy Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 62. Spain Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 63. Spain Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 64. Asia Pacific Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (K MT)
Figure 65. Asia Pacific Duchenne Muscular Dystrophy Drugs Sales Market Share by Region in 2024
Figure 66. Asia Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region in 2024
Figure 67. China Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 68. China Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 69. Japan Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 70. Japan Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 71. South Korea Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 72. South Korea Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 73. India Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 74. India Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 75. Southeast Asia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 76. Southeast Asia Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 77. South America Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (K MT)
Figure 78. South America Duchenne Muscular Dystrophy Drugs Sales Market Share by Country in 2024
Figure 79. South America Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate (M USD)
Figure 80. South America Duchenne Muscular Dystrophy Drugs Market Size by Country in 2024
Figure 81. Brazil Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 82. Brazil Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 83. Argentina Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 84. Argentina Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 85. Columbia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 86. Columbia Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 87. Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (K MT)
Figure 88. Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales Market Share by Region in 2024
Figure 89. Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate (M USD)
Figure 90. Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Size by Region in 2024
Figure 91. Saudi Arabia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 92. Saudi Arabia Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 93. UAE Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 94. UAE Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 95. Egypt Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 96. Egypt Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 97. Nigeria Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 98. Nigeria Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 99. South Africa Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 100. South Africa Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 101. Global Duchenne Muscular Dystrophy Drugs Production Market Share by Region (2020-2025)
Figure 102. North America Duchenne Muscular Dystrophy Drugs Production (K MT) Growth Rate (2020-2025)
Figure 103. Europe Duchenne Muscular Dystrophy Drugs Production (K MT) Growth Rate (2020-2025)
Figure 104. Japan Duchenne Muscular Dystrophy Drugs Production (K MT) Growth Rate (2020-2025)
Figure 105. China Duchenne Muscular Dystrophy Drugs Production (K MT) Growth Rate (2020-2025)
Figure 106. Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Volume (2020-2035) & (K MT)
Figure 107. Global Duchenne Muscular Dystrophy Drugs Market Size Forecast by Value (2020-2035) & (M USD)
Figure 108. Global Duchenne Muscular Dystrophy Drugs Sales Market Share Forecast by Type (2026-2035)
Figure 109. Global Duchenne Muscular Dystrophy Drugs Market Share Forecast by Type (2026-2035)
Figure 110. Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Application (2026-2035)
Figure 111. Global Duchenne Muscular Dystrophy Drugs Market Share Forecast by Application (2026-2035)